Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $4,810 | $795 | $1,798 | $2,435 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1,255 | $565 | $507 | $553 |
| Total Curr. Assets | $6,065 | $1,360 | $2,305 | $2,988 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $32 | $33 | $34 | $35 |
| Total NC Assets | $32 | $33 | $34 | $35 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $6,097 | $1,393 | $2,339 | $3,023 |
| Liabilities | – | – | – | – |
| Payables | $1,104 | $1,482 | $1,471 | $937 |
| Short-Term Debt | $0 | $0 | $112 | $222 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $695 | $352 |
| Total Curr. Liab. | $1,104 | $1,482 | $2,278 | $1,511 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $745 | $741 | $0 | $0 |
| Total NC Liab. | $745 | $741 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,849 | $2,223 | $2,278 | $1,511 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$85,464 | -$84,591 | -$83,633 | -$81,924 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $89,712 | $83,761 | $83,695 | $83,435 |
| Total Equity | $4,248 | -$830 | $62 | $1,512 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $6,097 | $1,393 | $2,339 | $3,023 |
| Net Debt | -$4,810 | -$795 | -$1,686 | -$2,213 |